A treatment regimen of Revlimid, melphalan and prednisone was found to be comparable to an autologous transplant without the recovery time and side effects associated with stem cell transplant
Friday, June 11, 2010
DATA PRESENTED CONFIRM REVLIMID’S OVERALL BENEFIT
Two large, randomized trials found patients patients treated with low-doses of Revlimid enjoyed a longer remission following stem cell transplant than those with placebo.
A treatment regimen of Revlimid, melphalan and prednisone was found to be comparable to an autologous transplant without the recovery time and side effects associated with stem cell transplant
A treatment regimen of Revlimid, melphalan and prednisone was found to be comparable to an autologous transplant without the recovery time and side effects associated with stem cell transplant
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment